Category: Therapeutic Area
Global Therapeutic Area
-
Women's Health Rehabilitation Products
... 2030, growing at a CAGR of 1.2% over the analysis period 2024-2030. Orthopedic Rehabilitation Products, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$731.9 Million by ... Read More
-
Breast Biopsy Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$983.4 Million by the end ... Read More
-
Food Allergy and Intolerance Products
... Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Lactose-Free, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$24.6 Billion by ... Read More
-
Dermatology Diagnostic Devices
... at a CAGR of 9.2% over the analysis period 2024-2030. Lasers, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$19.2 Billion by the end of the ... Read More
-
Adult Stores
... CAGR of 6.8% over the analysis period 2024-2030. Sex Toys, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$34.6 Billion by the end of the analysis ... Read More
-
Emergency Contraceptive Pills
... at a CAGR of 2.4% over the analysis period 2024-2030. Combination Pills, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$484.2 Million by the end of ... Read More
-
Rheumatoid Arthritis Therapeutics
... at a CAGR of 4.1% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
Breast Cancer Therapeutics
... at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of ... Read More
-
Cancer Gene Therapy
... at a CAGR of 20.9% over the analysis period 2024-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.7% CAGR and reach US$4.3 Billion by the end of ... Read More
-
Orthopedic Prosthetic Implants
... at a CAGR of 4.5% over the analysis period 2024-2030. Knee Prosthesis, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Anti-Infectives
... 6.2% over the analysis period 2024-2030. Anti-Viral Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$117.1 Billion by the end of the analysis period. Growth ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Aesthetic Services
... CAGR of 7.0% over the analysis period 2024-2030. Surgical, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$17.1 Billion by the end of the analysis period. ... Read More
-
Lumbosacral Orthosis (LSO)
... at a CAGR of 3.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$128.7 Million While China is Forecast to Grow at 5.6% CAGR The Lumbosacral Orthosis (LSO) market in the U.S. ... Read More
-
Human Growth Hormone Drugs
... 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the end ... Read More
-
Corporate Wellness
... CAGR of 6.5% over the analysis period 2024-2030. Health Risk Assessment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$27.9 Billion by the end of the ... Read More
-
Kidney Stone Management Devices
... 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Ureteroscopy, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$1.3 Billion by the end ... Read More
-
Overactive Bladder (OAB) Therapeutics
... 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Anticholinergics, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$614.7 Million by the end ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Bone Cement and Glue
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Bone Cement, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.1 Billion by the ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
-
Sepsis Therapeutics
... CAGR of 6.3% over the analysis period 2024-2030. Cephalosporin, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$3.1 Billion by the end of the analysis period. ... Read More
-
Testosterone Replacement Therapy (TRT)
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. TRT Injectables, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.6 Billion by the ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. IBS-D, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by ... Read More
-
Human Reproductive Technologies
... at a CAGR of 2.2% over the analysis period 2024-2030. Contraceptive Drugs & Devices, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$22.0 Billion by the ... Read More
Research Assistance
